Champions Oncology Growth, Revenue, Number of Employees and Funding

Overview

Location:
Hackensack, NJ USA
Total Funding:$36.8M
Industry:Biotech
Founded:2007
Lead Investor(s):National Securities Corporation
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Champions Oncology's estimated revenue is currently $20.2M per year.
  • Champions Oncology received $5.2M in venture funding in June 2016.
  • Champions Oncology's estimated revenue per employee is $187417
  • Champions Oncology's total funding is $36.8M.

Employee Data

  • Champions Oncology has 108 Employees.
  • Champions Oncology grew their employee count by 14% last year.
  • Champions Oncology currently has 21 job openings.

Executive Contacts

NameTitle
Maria ManciniVice President of Pharmacology
Neal GoodwinVice President Corporate Research Development
David MillerChief Financial Officer
Angela DaviesChief Medical Officer
Anna AmcheslavskyDirector of Business Development
Michelle MackSenior Director, Business Development
Mandy LehmannDirector of Business Development - Translational Oncology Solutions - Germany, Switzerland, Austria
Amy WesaDirector, Immuno-Oncology Research
Susan ForemanDirector of HR
Michael RitchieVice President, Global Head of Business Development

What Is Champions Oncology?

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Pharmaceuticals

108

Number of Employees

$20.2M

Revenue (est)

21

Current Jobs

14%

Employee Growth %

$36.8M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5283%
Hitachi Chemica...
$29.9M24213%
Canfield Scient...
$29.3M202-32%
Thomas Scientif...
$21.5M18123%
L Oreal USA
N/A0N/A
Insmed Incorpor...
$97.3M42111%
Amicus Therapeu...
$91.2M55417%$294.6M
Celularity
N/A14916%$367.7M
Legend Biotech ...
$12.8M98227%
ADMA Biologics
$23.1M16610%

Champions Oncology News

09/07/2019 - How Much is Champions Oncology, Inc.'s (NASDAQ:CSBR ...

Ronnie Morris has been the CEO of Champions Oncology, Inc. (NASDAQ:CSBR) since 2017. This report will, first, examine the CEO ...

09/08/2019 - Delving Into The Numbers For Oncimmune Holdings Plc (AIM ...

The Price to Book ratio for Champions Oncology, Inc. NasdaqCM:CSBR is 31.618851. The Price to book ratio is the current share price of a ...

09/06/2019 - Champions Oncology (NASDAQ:CSBR) Share Price Crosses ...

Champions Oncology Inc (NASDAQ:CSBR)'s share price passed below its 200-day moving average during trading on Thursday . The stock ...

Champions Oncology Funding

DateAmountRoundLead InvestorsReference
2013-01-31$9.3MUndisclosedArticle
2015-03-13$14.0MUndisclosedNew Enterprise AssociatesArticle
2016-06-13$5.2MUndisclosedNational Securities CorporationArticle

Champions Oncology Executive Hires

DateNameTitleReference
2011-11-02Gary G. GemignaniEVP/CFOArticle
2014-01-07Angela DaviesChief Medical OfficerArticle
2014-03-05Ido Ben-ZviDir Bioinformatics/Machine LearningArticle
2018-05-02Amy WesaDir Immuno-Oncology ResearchArticle

Champions Oncology New Location/Offices

DateLocationReference
2017-03-17Rockville, MDArticle